Aclaris Therapeutics

General Information
Business:

We are a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated topical drugs to address significant unmet needs in dermatology. Our lead drug candidate, A-101, is a proprietary high-concentration hydrogen peroxide topical solution that we are developing as a prescription treatment for seborrheic keratosis, or SK, a common non-malignant skin tumor. We have completed three Phase 2 clinical trials of A-101 in over 300 patients with SK. In these trials, following one or two applications of A-101, we observed clinically relevant and statistically significant improvements in clearing SK lesions on the face, trunk and extremities of the body. Clinically relevant means that the observed results suggest a potential meaningful medical benefit, and statistically significant means that there is a low statistical probability, typically less than 5%, that the observed results occurred by chance alone. We plan to commence three Phase 3 clinical trials of A-101 in patients with SK in the second half of 2015 and, if the results of these trials are favorable, to submit a New Drug Application, or NDA, for A-101 for the treatment of SK to the U.S. Food and Drug Administration, or FDA, in the second half of 2016.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 11
Founded: 2012
Contact Information
Address 101 Lindenwood Drive, Suite 400, Malvern, PA 19355, US
Phone Number (484) 324-7933
Web Address http://www.aclaristx.com
View Prospectus: Aclaris Therapeutics
Financial Information
Market Cap $213.5mil
Revenues $0.0 mil (last 12 months)
Net Income $-12.9 mil (last 12 months)
IPO Profile
Symbol ACRS
Exchange NASDAQ
Shares (millions): 5.0
Price range $11.00 - $11.00
Est. $ Volume $55.0 mil
Manager / Joint Managers Jefferies/ Citigroup
CO-Managers William Blair
Expected To Trade: 10/7/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change